Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | S100B | P04271 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25637658 | 0.81 | PKM (0.38) | PLK1CSNK2A1PLK3 | |
| SCHEMBL25056305 | 0.78 | PLK1 (0.46) | PLK1CSNK2A1PLK3CYP11B1CYP11B2 | |
| SCHEMBL25056163 | 0.78 | PLK1 (0.34) | PLK1CSNK2A1PLK3 | |
| SCHEMBL25056306 | 0.77 | PLK1 (0.48) | PLK1CSNK2A1PLK3CYP11B1CYP11B2 | |
| SCHEMBL25056148 | 0.77 | CYP11B1 (0.36) | PLK1CSNK2A1PLK3CYP11B1CYP11B2 | |
| SCHEMBL25056352 | 0.76 | PLK1 (0.35) | PLK1CSNK2A1PLK3CYP11B1CYP11B2 | |
| SCHEMBL25637930 | 0.76 | S100B (0.30) | S100B | |
| SCHEMBL25056409 | 0.74 | PLK1 (0.33) | PLK1CSNK2A1PLK3CYP11B1CYP11B2 | |
| SCHEMBL25056248 | 0.74 | PLK1 (0.33) | PLK1CSNK2A1PLK3CYP11B1CYP11B2 | |
| SCHEMBL25056259 | 0.73 | CYP11B1 (0.35) | PLK1CSNK2A1PLK3CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4137484-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PLK1 76/4885CSNK2A1 215/4885PLK3 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.